Isodiol (ISOLF) $0.25, Getting Into Phytoceuticals.

Isodiol International Inc. (ISOLF) $0.25

VANCOUVER, British Columbia, Sept. 05, 2017 (GLOBE NEWSWIRE) — Isodiol International Inc. (CSE:ISOL) (ISOLF) (LB6A.F) (the “Company” or “Isodiol”) a global cannabinoid innovator specializing in the development of pharmaceutical and consumer products announces that it is proud to be launching a new Phytoceutical Division that will focus on cannabinoids and terpenes derived from non-cannabis sources.

Proprietary extraction methods ensure that the cannabinoids and terpenes will not be denatured during extraction and this process will provide another superior product in the Isodiol offerings. The discovery of cannabinoids in non-cannabis plants and the proprietary methodology developed to extract them is a revolutionary development in the industry and will provide an opportunity to manufacture and distribute medicinal and consumer products into markets that presently have restrictions on such products.

Marcos Agramont, CEO, says “We are excited to be launching this new division and some of the first new products we will be bringing to the market will be CBD based which will not be derived from the cannabis plant. These highly innovative new products will open up our ability to sell into International markets much faster due to less regulations and restrictions surrounding our non-cannabis derived source of the CBD. In addition, we are confident in this new product line’s superb efficacy, which, in some cases, has demonstrated greater effectiveness than many cannabis derived products currently on the market.”

Read Full Press Release Here.

For more interesting curated articles like this, sign up for our free newsletter at the or click here to subscribe.